Гинекология (Jun 2014)
Cytomegalovirus infections: therapeutic potential in pregnancy
Abstract
The article presents the results of simultaneous clinical multicenter controlled study of comparative assessment of therapeutic efficacy, safety and tolerability Panavir, solution for intravenous injection of 0,04 mg/ml with the Standardl human immunoglobulin, intravenous solution in the complex treatment of cytomegalovirus infection in pregnant women in the II and III trimester. It was found that introduction of Panavir complex therapy effectively reduces acute cytomegalovirus infection titer immunoglobulin G and prevents infection of newborns, making it safe for both mother and fetus, and is not accompanied by side effects and adverse reactions.
